- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07937982
Protocol CAUSE-05 RHINO (RHINO)
Respiratory Health & Infant Nasal 'Omics (RHINO) (CAUSE-05)
CAUSE-05/RHINO is an observational study designed to learn how babies' nasal cells grow and change during the first months of life. The study will enroll pregnant mothers in their third trimester and their infants upon delivery for a target population of 60 mother-baby pairs. Researchers will conduct up to 6 study visits and collect serial nasal samples through 4 months of age.
Aperçu de l'étude
Statut
Les conditions
Description détaillée
This is an observational, multicenter study designed to assess developmental changes in in vivo and in cultured neonatal nasal epithelial cells. The study will enroll pregnant females in their third trimester of pregnancy as well as their infants upon delivery. Approximately 60 mother-infant pairs will be observed from birth to age 4 months to describe early-life developmental patterns of nasal cell gene expression, including genes related to type-II (T2) inflammation, immune response, and epithelial barrier function.
Type d'étude
Inscription (Estimé)
Contacts et emplacements
Coordonnées de l'étude
- Nom: James E Gern, MD
- Numéro de téléphone: 608-263-6201
- E-mail: gern@medicine.wisc.edu
Lieux d'étude
-
-
Illinois
-
Chicago, Illinois, États-Unis, 60611
- Ann & Robert H. Lurie Children's Hospital of Chicago
-
Chercheur principal:
- Rajesh Kumar, MD
-
Contact:
- Sarah Godley
- Numéro de téléphone: 312-227-6454
- E-mail: sgodley@luriechildrens.org
-
-
Missouri
-
St Louis, Missouri, États-Unis, 63110
- Washington University at St. Louis
-
Contact:
- Gina Simpson
- Numéro de téléphone: 314-362-9139
- E-mail: simpsong@wustl.edu
-
Chercheur principal:
- Katherine Rivera-Spoljaric, MD
-
-
Ohio
-
Cincinnati, Ohio, États-Unis, 45229
- Cincinnati Children's Hospital Medical Center
-
Chercheur principal:
- Neeru Hershey, MD
-
Contact:
- Molly Brausch-Bradner
- Numéro de téléphone: 513-803-0028
- E-mail: molly.brausch-bradner@cchmc.org
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
Méthode d'échantillonnage
Population étudiée
Pregnant maternal participants from the pre-selected recruitment census tracts designated by the CAUSE program, aged 18 years or older, with a gestational age greater than or equal to 28 weeks, in addition to one offspring of each maternal participant.
La description
Inclusion Criteria:
-
Able to understand and provide informed consent
-
Age 18 years or older
-
Currently pregnant, with:
- Gestational age ≥ 28 weeks as confirmed by participant self-report
- Intent to deliver at a participating clinical site labor and delivery (L&D) center
-
Agrees to enroll infant into the study at birth
-
In the case of multiple gestation, agrees to enroll only one infant who will be randomly selected
-
Have a primary place of residence in one of the pre-selected recruitment census tracts as outlined in the Protocol CAUSE-05 (RHINO) Manual of Procedures (MOP) a. Participants who do not live in the pre-selected census tracts but live within the Office of Management and Budget (OMB) defined Metropolitan Statistical Area and have publicly funded health insurance will qualify for inclusion.
Exclusion Criteria:
- Inability or unwillingness to give written informed consent or comply with study protocol
- Insufficient proficiency in English or Spanish to provide informed consent and complete study procedures
- Obstetric complications present and/or anticipated that could, in the opinion of the investigator, impact the study objectives
- Pregnancy conceived via donor oocyte (egg donation)
- Known plans to move outside the pre-selected recruitment census tracts before the infant reaches 4 months of age
- Intent to transfer infant custody (e.g., via adoption or foster placement) within 4 months of birth
- Past or current medical problems that are not listed above, which, in the opinion of the investigator, may pose additional risks related to participation in the study, may interfere with the participant's ability to comply with the protocol, or may impact the interpretation of data obtained from the study.
Infants who meet any of the following criteria at the Birth Visit are not eligible for further study participation:
- Delivery before 36 weeks gestation
- Diagnosed at birth with any medical condition which, in the opinion of the investigator, may pose additional risks related to participation in the study, may interfere with the family's ability to comply with the protocol, or may impact the interpretation of data obtained from the study.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Modèles d'observation: COHORT
- Perspectives temporelles: PROSPECTIVE
Cohortes et interventions
Groupe / Cohorte |
|---|
|
Pregnant females 18 years and older and their infants upon delivery
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Gene expression of nasal swab RNA samples
Délai: 4 months
|
Gene expression will be measured by whole transcriptome RNA sequencing |
4 months
|
Collaborateurs et enquêteurs
Les enquêteurs
- Chaise d'étude: James E Gern, MD, University of Wisconsin, Madison
- Chaise d'étude: Jo L Wilson, MD, University of Wisconsin, Madison
- Directeur d'études: Daniel Jackson, MD, University of Wisconsin, Madison
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Estimé)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- DAIT CAUSE-05
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
Immunonology Database and Analysis Portal (ImmPort), a long-term archive of clinical and mechanistic data from DAIT-funded grants and contracts.
Délai de partage IPD
On average, within 24 months after database lock for the trial.
Critères d'accès au partage IPD
Open access
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .